Temps réel estimé
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
201,4 USD | -0,28 % | +5,30 % | -22,48 % |
18:10 | BIOGEN INC. : Goldman Sachs maintient son opinion neutre | ZM |
18:07 | BIOGEN INC. : Opinion positive de Canaccord Genuity | ZM |
Métier
- ventes de médicaments (73,7%) : destinés au traitement de la sclérose en plaques, du psoriasis chronique chez l'adulte, de la polyarthrite rhumatoïde, des cancers, etc. ;
- royalties (17,2%) ;
- autres (9,1%) : notamment revenus issus d'accords de partenariats.
Nombre d'employés: 7 570
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 10 173 | 100,0 % | 9 836 | 100,0 % | -3,32 % |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
55,2
%
| 5 532 | 54,4 % | 5 434 | 55,2 % | -1,77 % |
Europe
21,8
%
| 2 413 | 23,7 % | 2 140 | 21,8 % | -11,34 % |
Germany
8,8
%
| 926 | 9,1 % | 868 | 8,8 % | -6,28 % |
Asia
8,8
%
| 720 | 7,1 % | 863 | 8,8 % | +19,97 % |
Other
5,4
%
| 583 | 5,7 % | 531 | 5,4 % | -8,87 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | 64 | 14/11/22 | |
Director of Finance/CFO | 60 | 15/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 01/01/15 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02/10/23 |
Chuck Triano
IRC | Investor Relations Contact | - | 10/04/23 |
Michael Hencke
IRO | Public Communications Contact | - | 01/07/12 |
Michael Dambach
TRE | Treasurer | 57 | 01/01/07 |
Corporate Secretary | - | - | |
Robert Kilo
PRN | Corporate Officer/Principal | - | - |
Rachid Izzar
PRN | Corporate Officer/Principal | - | 01/01/21 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01/01/10 |
William Hawkins
BRD | Director/Board Member | 70 | 19/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 03/01/10 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 20/03/10 |
Chief Executive Officer | 64 | 14/11/22 | |
Maria Freire
BRD | Director/Board Member | 69 | 02/06/21 |
Director/Board Member | 54 | 01/01 | |
Jesus B. Mantas
BRD | Director/Board Member | 55 | 19/06/19 |
Susan Langer
BRD | Director/Board Member | - | 26/06/23 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 169 160 798 | 144 360 393 ( 85,34 %) | 23 800 000 ( 14,07 %) | 85,34 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
DENALI THERAPEUTICS INC. 9,16% | 12 751 365 | 9,16% | 261 658 010 $ |
SAGE THERAPEUTICS, INC. 10,38% | 6 241 473 | 10,38% | 116 965 204 $ |
14 652 466 | 7,19% | 9 817 152 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. |
Biotechnology
|
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. |
Pharmaceuticals: Major
|
Secteur
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
-22,66 % | 29,36 Md | |
-2,86 % | 87,31 Md | |
+2,63 % | 40,86 Md | |
+58,56 % | 24,49 Md | |
-14,02 % | 17,31 Md | |
-18,78 % | 11,62 Md | |
-15,61 % | 11,31 Md | |
-44,02 % | 11,26 Md | |
+5,17 % | 8,31 Md | |
-9,82 % | 7,9 Md |
- Bourse
- Actions
- Action BIIB
- Société Biogen Inc.